Defunct Company
Total Trials
15
As Lead Sponsor
0
As Collaborator
Total Enrollment
1,178
NCT01593254
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Phase: Phase 2
Role: Collaborator
Start: Sep 12, 2012
Completion: Apr 12, 2022
NCT02349386
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
Start: Jul 31, 2015
Completion: Jan 10, 2018
NCT02725593
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
Phase: Phase 3
Start: Jun 22, 2016
Completion: Apr 6, 2020
NCT03184987
A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
Start: Jun 22, 2017
Completion: Jun 25, 2019
NCT03029247
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
Start: Jul 27, 2017
Completion: Jul 9, 2020
NCT03202004
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
Start: Jan 22, 2018
Completion: Sep 28, 2018
NCT03815318
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
Start: Jan 21, 2019
Completion: Jan 16, 2020
NCT04731298
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
Start: May 25, 2021
Completion: Apr 21, 2022
NCT05003310
ConsideRAte Study - Splenic Stimulation for RA
Phase: N/A
Start: Oct 19, 2021
Completion: Apr 30, 2032
NCT05188729
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Start: Feb 1, 2022
Completion: Apr 15, 2024
NCT06125717
Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP
Phase: Phase 1
Start: Jul 2, 2022
Completion: Mar 13, 2023
NCT05561764
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
Phase: Phase 4
Start: Jan 3, 2023
Completion: Dec 11, 2024
NCT05909644
An Open-label DDI Study of Omaveloxolone in Healthy Subjects
Start: Jul 5, 2023
Completion: Aug 30, 2023
NCT05927649
A TQTc Study for Omaveloxolone
Start: Jul 11, 2023
Completion: Sep 1, 2023
NCT06436911
To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
Phase: Phase 1/2
Start: Aug 31, 2024
Completion: Jul 31, 2026